Literature DB >> 15122207

The discovery of receptor tyrosine kinases: targets for cancer therapy.

Andreas Gschwind1, Oliver M Fischer, Axel Ullrich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15122207     DOI： 10.1038/nrc1360

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  358 in total

1.  Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.

Authors:  Xianzhou Song; Hua Wang; Craig D Logsdon; Asif Rashid; Jason B Fleming; James L Abbruzzese; Henry F Gomez; Douglas B Evans; Huamin Wang
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

2.  Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs.

Authors:  Sheldon R Mink; Surabhi Vashistha; Wenxuan Zhang; Amanda Hodge; David B Agus; Anjali Jain
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

3.  Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.

Authors:  Qi-Wen Fan; William A Weiss
Journal:  Methods Mol Biol       Date:  2012

4.  N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.

Authors:  Aleem Gangjee; Nilesh Zaware; Sudhir Raghavan; Jie Yang; Jessica E Thorpe; Michael A Ihnat
Journal:  Bioorg Med Chem       Date:  2012-02-04       Impact factor: 3.641

5.  Review.

Authors:  Sujal Rangwalla; Cheryl E Gariepy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

6.  EGFR signals to mTOR through PKC and independently of Akt in glioma.

Authors:  Qi-Wen Fan; Christine Cheng; Zachary A Knight; Daphne Haas-Kogan; David Stokoe; C David James; Frank McCormick; Kevan M Shokat; William A Weiss
Journal:  Sci Signal       Date:  2009-01-27       Impact factor: 8.192

7.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Authors:  Peter Vajkoczy; Pjotr Knyazev; Andrea Kunkel; Hans-Holger Capelle; Sandra Behrndt; Hendrik von Tengg-Kobligk; Fabian Kiessling; Uta Eichelsbacher; Marco Essig; Tracy-Ann Read; Ralf Erber; Axel Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

Review 8.  Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression.

Authors:  Cassandra L Buchheit; Kelsey J Weigel; Zachary T Schafer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

9.  Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.

Authors:  Kojo S J Elenitoba-Johnson; David K Crockett; Jonathan A Schumacher; Stephen D Jenson; Cheryl M Coffin; Alan L Rockwood; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

Review 10.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.